Norgen Biotek Corp

Norgen Biotek Corp is a Canadian for-profit biotechnology manufacturer headquartered in Thorold, Ontario, with a registered facility in Bethesda, Maryland. The company specializes in providing advanced molecular biology services to the National Institutes of Health, with a particular focus on exosomal RNA extraction, isolation, purification, and characterization. Since registering with SAM.gov in August 2008, Norgen Biotek has established itself as a reliable vendor for federal biomedical research initiatives, consistently delivering specialized services that support clinical studies and RNA sequencing projects across multiple NIH institutes.

Norgen Biotek's federal contract portfolio demonstrates substantial engagement with the National Human Genome Research Institute (NHGRI), which has awarded the company five documented purchase orders totaling approximately $1.09 million. The most recent award, issued on September 19, 2025, is a $156,600 firm fixed-price purchase order for small RNA characterization of urinary exosomes with an ultimate completion date of September 18, 2026. Prior to this, the company received a $668,710 contract in May 2023 to extract and isolate intact RNA exosomes from plasma samples to support National Heart, Lung and Blood Institute clinical research, as well as a $119,200 award in August 2021 for exosome extraction services supporting future RNA sequencing work. Additionally, Norgen Biotek received a $41,395.20 purchase order in January 2022 and a $16,821.83 award in September 2023 from the National Institute of Diabetes and Digestive and Kidney Diseases for exosomal RNA purification services. All of these contracts were awarded without set-aside designations, indicating competitive procurement processes open to all qualified contractors. No subcontractors have been identified on any of the awards, and the company has consistently performed work at its own facilities rather than in partnership with prime contractors.